Inventor · disambiguated record
Marcus A. Van Dijk
Also filed as: VAN DIJK MARCUS A · VAN DIJK MARCUS ANTONIUS
10 granted patents·1 pending application·743 citations·filing 2002–2013
92Inventor score
Top patents by PatentIndex Score
11 records- 0198US7247301B2Human monoclonal antibodies to epidermal growth factor receptor (EGFR)GENMAB AS·Filed 2002·Granted Jul 24, 2007·215 cites·24 claims
- 0298US7153507B2Human antibodies specific for interleukin 15 (IL-15)GENMAB AS·Filed 2002·Granted Dec 26, 2006·367 cites·32 claims
- 0394US7595378B2Human monoclonal antibodies to epidermal growth factor receptor (EGFR)GENMAB AS·Filed 2002·Granted Sep 29, 2009·64 cites·14 claims
- 0491US7192582B2Human monoclonal antibodies to FC alpha receptor (CD89)MEDAREX INC·Filed 2002·Granted Mar 20, 2007·52 cites·16 claims
- 0585US7329405B2Human antibodies specific for interleukin 15 (IL-15)GENMAB AS·Filed 2003·Granted Feb 12, 2008·11 cites·10 claims
- 0685US7247304B2Methods of treating using anti-IL-15 antibodiesGENMAB AS·Filed 2003·Granted Jul 24, 2007·21 cites·18 claims
- 0784US7585961B2Nucleic acid encoding human antibodies specific for interleukin 15 (IL-15)GENMAB AS·Filed 2007·Granted Sep 8, 2009·5 cites·22 claims
- 0879US8586041B2Human monoclonal antibodies to epidermal growth factor receptor (EGFR)VAN DE WINKEL JAN G J·Filed 2009·Granted Nov 19, 2013·5 cites·23 claims
- 0977US9458236B2Human monoclonal antibodies to epidermal growth factor receptor (EGFR)GENMAB AS·Filed 2013·Granted Oct 4, 2016·2 cites·20 claims
- 1074US7597892B2Method for treating psoriasis by administering human antibodies specific for Interleukin 15 (IL-15)GENMAB AS·Filed 2007·Granted Oct 6, 2009·1 cites·13 claims
- 1147US2007253958A1Human monoclonal antibodies to FC gamma receptor II (CD32)MEDAREX INC·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marcus A. Van Dijk files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →